B-intervention	0	8	Exercise
O	9	18	following
O	19	25	breast
O	26	32	cancer
O	32	33	:
O	34	45	exploratory
O	46	54	survival
O	55	63	analyses
O	64	66	of
O	67	70	two
O	71	81	randomised
O	81	82	,
O	83	93	controlled
O	94	100	trials
O	100	101	.

O	102	105	The
O	106	114	Exercise
O	115	118	for
O	119	125	Health
O	126	132	trials
O	133	137	were
O	138	148	randomised
O	148	149	,
O	150	160	controlled
O	161	167	trials
O	168	176	designed
O	177	179	to
O	180	188	evaluate
O	189	191	an
O	192	193	8
O	193	194	-
O	194	199	month
O	200	209	pragmatic
O	210	218	exercise
O	219	231	intervention
O	231	232	,
O	233	243	commencing
O	244	245	6
O	246	251	weeks
O	252	256	post
O	256	257	-
O	257	264	surgery
O	265	268	for
B-eligibility	269	274	women
I-eligibility	275	279	with
I-eligibility	280	285	newly
I-eligibility	286	295	diagnosed
I-eligibility	296	302	breast
I-eligibility	303	309	cancer
O	310	318	residing
O	319	321	in
O	322	327	urban
O	328	330	or
O	331	336	rural
O	336	337	/
O	337	345	regional
B-location	346	355	Australia
O	355	356	.

O	357	360	For
O	361	366	these
O	367	378	exploratory
O	379	387	analyses
O	387	388	,
O	389	392	the
O	393	400	primary
O	401	404	and
O	405	414	secondary
O	415	423	outcomes
O	424	428	were
B-outcome-Measure	429	436	overall
I-outcome-Measure	437	445	survival
I-outcome-Measure	446	447	(
I-outcome-Measure	447	449	OS
I-outcome-Measure	449	450	)
O	451	454	and
B-outcome-Measure	455	462	disease
I-outcome-Measure	462	463	-
I-outcome-Measure	463	467	free
I-outcome-Measure	468	476	survival
I-outcome-Measure	477	478	(
I-outcome-Measure	478	481	DFS
I-outcome-Measure	481	482	)
O	482	483	,
O	484	496	respectively
O	496	497	.

O	498	508	Consenting
O	509	514	urban
O	514	515	-
O	516	517	(
O	517	518	n
O	519	520	=
B-total-participants	521	524	194
O	524	525	)
O	526	529	and
O	530	535	rural
O	535	536	/
O	536	544	regional
O	544	545	-
O	545	553	residing
O	554	559	women
O	560	561	(
O	561	562	n
O	563	564	=
B-total-participants	565	568	143
O	568	569	)
O	570	574	were
O	575	585	randomised
O	586	588	to
O	589	597	exercise
O	598	599	(
O	599	611	intervention
O	612	621	delivered
O	622	626	face
O	626	627	-
O	627	629	to
O	629	630	-
O	630	634	face
O	635	637	or
O	638	640	by
O	641	650	telephone
O	650	651	)
O	652	654	or
B-control	655	660	usual
I-control	661	665	care
O	665	666	.

O	667	670	Cox
O	671	683	proportional
O	684	691	hazards
O	692	698	models
O	699	703	were
O	704	708	used
O	709	711	to
O	712	720	estimate
O	721	727	hazard
O	728	734	ratios
O	735	736	(
O	736	739	HRs
O	739	740	)
O	741	744	and
O	745	747	95
O	747	748	%
O	749	759	confidence
O	760	769	intervals
O	770	771	(
O	771	773	CI
O	773	774	)
O	775	778	for
O	779	787	survival
O	788	796	outcomes
O	797	798	(
O	798	806	exercise
O	807	812	group
O	812	813	,
O	814	815	n
O	816	817	=
B-intervention-participants	818	821	207
O	821	822	,
O	823	825	65
O	825	826	%
O	827	832	urban
O	833	838	women
O	838	839	;
O	840	845	usual
O	846	850	care
O	851	856	group
O	856	857	,
O	858	859	n
O	860	861	=
B-control-participants	862	865	130
O	865	866	,
O	867	869	46
O	869	870	%
O	871	876	urban
O	877	882	women
O	882	883	)
O	883	884	.

O	885	890	After
O	891	892	a
O	893	899	median
O	900	906	follow
O	906	907	-
O	907	909	up
O	910	912	of
O	913	914	8
O	914	915	.
O	915	916	3
O	917	922	years
O	922	923	,
O	924	929	there
O	930	934	were
B-iv-bin-abs	935	937	11
O	938	939	(
B-iv-bin-percent	939	940	5
I-iv-bin-percent	940	941	.
I-iv-bin-percent	941	942	3
I-iv-bin-percent	942	943	%
O	943	944	)
B-outcome	945	951	deaths
O	952	954	in
O	955	958	the
O	959	967	exercise
O	968	973	group
O	974	982	compared
O	983	987	with
B-cv-bin-abs	988	990	15
O	991	992	(
B-cv-bin-percent	992	994	11
I-cv-bin-percent	994	995	.
I-cv-bin-percent	995	996	5
I-cv-bin-percent	996	997	%
O	997	998	)
O	999	1005	deaths
O	1006	1008	in
O	1009	1012	the
O	1013	1018	usual
O	1019	1023	care
O	1024	1029	group
O	1030	1031	(
O	1031	1033	OS
O	1034	1036	HR
O	1037	1040	for
O	1041	1044	the
O	1045	1053	exercise
O	1054	1059	group
O	1059	1060	:
O	1061	1062	0
O	1062	1063	.
O	1063	1065	45
O	1065	1066	,
O	1067	1069	95
O	1069	1070	%
O	1071	1073	CI
O	1074	1075	0
O	1075	1076	.
O	1076	1078	20
O	1078	1079	-
O	1079	1080	0
O	1080	1081	.
O	1081	1083	96
O	1083	1084	;
O	1085	1086	p
O	1087	1088	=
O	1089	1090	0
O	1090	1091	.
O	1091	1093	04
O	1093	1094	)
O	1094	1095	.

B-outcome	1096	1099	DFS
I-outcome	1100	1106	events
O	1107	1110	for
O	1111	1114	the
O	1115	1123	exercise
O	1124	1130	versus
O	1131	1136	usual
O	1137	1141	care
O	1142	1147	group
O	1148	1152	were
B-iv-bin-abs	1153	1155	25
O	1156	1157	(
B-iv-bin-percent	1157	1159	12
I-iv-bin-percent	1159	1160	.
I-iv-bin-percent	1160	1161	1
I-iv-bin-percent	1161	1162	%
O	1162	1163	)
O	1164	1167	and
B-cv-bin-abs	1168	1170	23
O	1171	1172	(
B-cv-bin-percent	1172	1174	17
I-cv-bin-percent	1174	1175	.
I-cv-bin-percent	1175	1176	7
I-cv-bin-percent	1176	1177	%
O	1177	1178	)
O	1178	1179	,
O	1180	1192	respectively
O	1193	1194	(
O	1194	1196	HR
O	1196	1197	:
O	1198	1199	0
O	1199	1200	.
O	1200	1202	66
O	1202	1203	,
O	1204	1206	95
O	1206	1207	%
O	1208	1210	CI
O	1211	1212	0
O	1212	1213	.
O	1213	1215	38
O	1215	1216	-
O	1216	1217	1
O	1217	1218	.
O	1218	1220	17
O	1220	1221	;
O	1222	1223	p
O	1224	1225	=
O	1226	1227	0
O	1227	1228	.
O	1228	1230	16
O	1230	1231	)
O	1231	1232	.

O	1233	1236	HRs
O	1237	1240	for
O	1241	1243	OS
O	1244	1252	favoured
O	1253	1261	exercise
O	1262	1274	irrespective
O	1275	1277	of
O	1278	1281	age
O	1281	1282	,
O	1283	1287	body
O	1288	1292	mass
O	1293	1298	index
O	1298	1299	,
O	1300	1305	stage
O	1306	1308	of
O	1309	1316	disease
O	1316	1317	,
O	1318	1330	intervention
O	1331	1341	compliance
O	1341	1342	,
O	1343	1346	and
O	1347	1355	physical
O	1356	1364	activity
O	1365	1371	levels
O	1372	1374	at
O	1375	1377	12
O	1378	1384	months
O	1385	1389	post
O	1389	1390	-
O	1390	1399	diagnosis
O	1399	1400	,
O	1401	1409	although
O	1410	1414	were
O	1415	1423	stronger
O	1424	1425	(
O	1425	1426	p
O	1427	1428	<
O	1429	1430	0
O	1430	1431	.
O	1431	1433	05
O	1433	1434	)
O	1435	1438	for
O	1439	1446	younger
O	1447	1452	women
O	1452	1453	,
O	1454	1459	women
O	1460	1464	with
O	1465	1470	stage
O	1471	1473	II
O	1474	1475	+
O	1476	1483	disease
O	1483	1484	,
O	1485	1490	women
O	1491	1495	with
O	1496	1497	1
O	1498	1499	+
O	1500	1511	comorbidity
O	1512	1514	at
O	1515	1519	time
O	1520	1522	of
O	1523	1532	diagnosis
O	1532	1533	,
O	1534	1540	higher
O	1541	1553	intervention
O	1554	1564	compliance
O	1565	1568	and
O	1569	1572	for
O	1573	1578	those
O	1579	1582	who
O	1583	1586	met
O	1587	1595	national
O	1596	1604	physical
O	1605	1613	activity
O	1614	1624	guidelines
O	1625	1627	at
O	1628	1630	12
O	1631	1637	months
O	1638	1642	post
O	1642	1643	-
O	1643	1652	diagnosis
O	1652	1653	.

O	1654	1656	An
O	1657	1665	exercise
O	1666	1678	intervention
O	1679	1688	delivered
O	1689	1695	during
O	1696	1699	and
O	1700	1706	beyond
O	1707	1716	treatment
O	1717	1720	for
O	1721	1727	breast
O	1728	1734	cancer
O	1734	1735	,
O	1736	1739	and
O	1740	1744	that
O	1745	1748	was
O	1749	1757	designed
O	1758	1760	to
O	1761	1766	cater
O	1767	1770	for
O	1771	1774	all
O	1775	1780	women
O	1781	1793	irrespective
O	1794	1796	of
O	1797	1802	place
O	1803	1805	of
O	1806	1815	residence
O	1816	1819	and
O	1820	1826	access
O	1827	1829	to
O	1830	1836	health
O	1837	1845	services
O	1845	1846	,
O	1847	1850	has
O	1851	1856	clear
O	1857	1866	potential
O	1867	1869	to
O	1870	1877	benefit
O	1878	1886	survival
O	1886	1887	.

O	1888	1893	Trial
O	1894	1901	numbers
O	1901	1902	:
O	1903	1906	ACT
O	1907	1909	RN
O	1909	1910	:
O	1911	1926	012606000233527
O	1926	1927	;
O	1928	1931	ACT
O	1932	1934	RN
O	1934	1935	:
O	1936	1950	12609000809235
O	1950	1951	.
